Tumor metastasis: Moving new biological insights into the clinic

Nature Medicine

Volumn 19, Issue 11, 2013, Pages 1450-1464

  Wan, Liling ^a   Pantel, Klaus ^b   Kang, Yibin ^c  

^a PRINCETON UNIVERSITY   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR; GELATINASE A; GLYCOPROTEIN GP 130; HISTONE DEACETYLASE; INTERSTITIAL COLLAGENASE; K RAS PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; STAT3 PROTEIN; STROMELYSIN; STROMELYSIN 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANTIANGIOGENIC THERAPY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER OF UNKNOWN PRIMARY SITE; CANCER RECURRENCE; CANCER STEM CELL; CARCINOGENESIS; CELL ADHESION; CELL DIFFERENTIATION; CELL INVASION; COLON CANCER; EPITHELIAL MESENCHYMAL TRANSITION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GLIOBLASTOMA; HUMAN; LUNG CANCER; METASTASIS; MICROMETASTASIS; MINIMAL RESIDUAL DISEASE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; STROMA CELL; TESTIS CANCER; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; UNFOLDED PROTEIN RESPONSE; WNT SIGNALING PATHWAY;

CELL SURVIVAL; DRUG DISCOVERY; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; ONCOGENES; STROMAL CELLS; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MICROENVIRONMENT;

EID: 84887421660     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3391     Document Type: Review

References (239)

1. Disibio, G. & French, S.W. Metastatic patterns of cancers: results from a large autopsy study. Arch. Pathol. Lab. Med. 132, 931-939 (2008).
2. Chen, H., Shah, A.S., Girgis, R.E. & Grossman, S.A. Transmission of glioblastoma multiforme after bilateral lung transplantation. J. Clin. Oncol. 26, 3284-3285 (2008).
3. Smid, M. et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 68, 3108-3114 (2008).
4. Perou, C.M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
5. van de Vijver, M.J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
6. Sørlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98, 10869-10874 (2001).
7. Wang, Z.A. et al. Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat. Cell Biol. 15, 274-283 (2013).
8. Lim, E. et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 15, 907-913 (2009).
9. Molyneux, G. et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7, 403-417 (2010).
10. Hunter, K. Host genetics influence tumour metastasis. Nat. Rev. Cancer 6, 141-146 (2006).
11. Winter, S.F., Lukes, L., Walker, R.C., Welch, D.R. & Hunter, K.W. Allelic variation and differential expression of the mSIN3A histone deacetylase complex gene Arid4b promote mammary tumor growth and metastasis. PLoS Genet. 8, e1002735 (2012).
12. Goldberger, N., Walker, R.C., Kim, C.H., Winter, S. & Hunter, K.W. Inherited variation in miR-290 expression suppresses breast cancer progression by targeting the metastasis susceptibility gene Arid4b. Cancer Res. 73, 2671-2681 (2013).
13. Faraji, F. et al. Cadm1 is a metastasis susceptibility gene that suppresses metastasis by modifying tumor interaction with the cell-mediated immunity. PLoS Genet. 8, e1002926 (2012).
14. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
15. Slamon, D.J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
16. Chapman, P.B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
17. Kwak, E.L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
18. Ithimakin, S. et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res. 73, 1635-1646 (2013).
19. Braun, S. et al. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res. 61, 1890-1895 (2001).
20. Gasch, C. et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin. Chem. 59, 252-260 (2013).
21. Lito, P. et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22, 668-682 (2012).
22. Gupta, G.P. & Massague, J. Cancer metastasis: building a framework. Cell 127, 679-695 (2006).
23. Chambers, A.F., Groom, A.C. & MacDonald, I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563-572 (2002).
24. Friedl, P. & Wolf, K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer 3, 362-374 (2003).
25. Friedl, P., Locker, J., Sahai, E. & Segall, J.E. Classifying collective cancer cell invasion. Nat. Cell Biol. 14, 777-783 (2012).
26. Christiansen, J.J. & Rajasekaran, A.K. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 66, 8319-8326 (2006).
27. Giampieri, S. et al. Localized and reversible TGFb signalling switches breast cancer cells from cohesive to single cell motility. Nat. Cell Biol. 11, 1287-1296 (2009).
28. Thiery, J.P., Acloque, H., Huang, R.Y. & Nieto, M.A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890 (2009).
29. Pencheva, N. & Tavazoie, S.F. Control of metastatic progression by microRNA regulatory networks. Nat. Cell Biol. 15, 546-554 (2013).
30. Tam, W.L. & Weinberg, R.A. Epigenetics of epithelial-mesenchymal plasticity in cancer. Nat. Med. 19, 1438-1449 (2013).
31. De Craene, B. & Berx, G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 13, 97-110 (2013).
32. Brabletz, T. To differentiate or not-routes towards metastasis. Nat. Rev. Cancer 12, 425-436 (2012).
33. Scheel, C. & Weinberg, R.A. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin. Cancer Biol. 22, 396-403 (2012).
34. Ledford, H. Cancer theory faces doubts. Nature 472, 273 (2011).
35. Brabletz, T. et al. Variable b-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. USA 98, 10356-10361 (2001).
36. Bednarz-Knoll, N., Alix-Panabieres, C. & Pantel, K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev. 31, 673-687 (2012).
37. Yokobori, T. et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 73, 2059-2069 (2013).
38. Yu, M. et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580-584 (2013).
39. Kessenbrock, K., Plaks, V. & Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52-67 (2010).
40. Boyd, N.F. et al. Heritability of mammographic density, a risk factor for breast cancer. N. Engl. J. Med. 347, 886-894 (2002).
41. Provenzano, P.P. et al. Collagen density promotes mammary tumor initiation and progression. BMC Med. 6, 11 (2008).
42. Levental, K.R. et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891-906 (2009).
43. Gao, Y. et al. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc. Natl. Acad. Sci. USA 107, 18892-18897 (2010).
44. Gilkes, D.M. et al. Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis. Mol. Cancer Res. 11, 456-466 (2013).
45. Erler, J.T. et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440, 1222-1226 (2006).
46. Lu, P., Weaver, V.M. & Werb, Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 196, 395-406 (2012).
47. Weis, S.M. & Cheresh, D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 17, 1359-1370 (2011).
48. Sonoshita, M. et al. Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. Cancer Cell 19, 125-137 (2011).
49. Reymond, N. et al. Cdc42 promotes transendothelial migration of cancer cells through b1 integrin. J. Cell Biol. 199, 653-668 (2012).
50. Valastyan, S. & Weinberg, R.A. Tumor metastasis: molecular insights and evolving paradigms. Cell 147, 275-292 (2011).
51. Minn, A.J. et al. Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524 (2005).
52. Padua, D. et al. TGFb primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133, 66-77 (2008).
53. Gupta, G.P. et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446, 765-770 (2007).
54. Douma, S. et al. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430, 1034-1039 (2004).
55. Bos, P.D. et al. Genes that mediate breast cancer metastasis to the brain. Nature 459, 1005-1009 (2009).
56. Chen, Q., Zhang, X.H. & Massague, J. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 20, 538-549 (2011).
57. Grabinski, N. et al. Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells. Cell. Signal. 23, 1952-1960 (2011).
58. Chao, M.P., Weissman, I.L. & Majeti, R. The CD47-SIRPa pathway in cancer immune evasion and potential therapeutic implications. Curr. Opin. Immunol. 24, 225-232 (2012).
59. Baccelli, I. et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol. 31, 539-544 (2013).
60. Weiskopf, K. et al. Engineered SIRPa variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341, 88-91 (2013).
61. Pantel, K. & Brakenhoff, R.H. Dissecting the metastatic cascade. Nat. Rev. Cancer 4, 448-456 (2004).
62. Aguirre-Ghiso, J.A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7, 834-846 (2007).
63. Shibue, T., Brooks, M.W., Inan, M.F., Reinhardt, F. & Weinberg, R.A. The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions. Cancer Discov. 2, 706-721 (2012).
64. Shibue, T. & Weinberg, R.A. Integrin b1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc. Natl. Acad. Sci. USA 106, 10290-10295 (2009).
65. Barkan, D. et al. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res. 68, 6241-6250 (2008).
66. Barkan, D. et al. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res. 70, 5706-5716 (2010).
67. Aguirre Ghiso, J.A., Kovalski, K. & Ossowski, L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 147, 89-104 (1999).
68. Ranganathan, A.C., Adam, A.P., Zhang, L. & Aguirre-Ghiso, J.A. Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells? Cancer Biol. Ther. 5, 729-735 (2006).
69. Sosa, M.S., Avivar-Valderas, A., Bragado, P., Wen, H.C. & Aguirre-Ghiso, J.A. ERK1/2 and p38a/b signaling in tumor cell quiescence: opportunities to control dormant residual disease. Clin. Cancer Res. 17, 5850-5857 (2011).
70. Gao, H. et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 150, 764-779 (2012).
71. Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 (2003).
72. Sethi, N., Dai, X., Winter, C.G. & Kang, Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 19, 192-205 (2011).
73. Tabariès, S. et al. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene 30, 1318-1328 (2011).
74. Lu, X. et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging a4b1-positive osteoclast progenitors. Cancer Cell 20, 701-714 (2011).
75. Shiozawa, Y. et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 121, 1298-1312 (2011).
76. Balic, M. et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12, 5615-5621 (2006).
77. Hanahan, D. & Coussens, L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322 (2012).
78. Quail, D.F. & Joyce, J.A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 45-59 (2013).
79. Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14, 518-527 (2008).
80. Fidler, I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3, 453-458 (2003).
81. Wyckoff, J. et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 64, 7022-7029 (2004).
82. DeNardo, D.G. et al. CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16, 91-102 (2009).
83. Dirat, B. et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 71, 2455-2465 (2011).
84. Karnoub, A.E. et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557-563 (2007).
85. Nieman, K.M. et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17, 1498-1503 (2011).
86. Luga, V. et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 151, 1542-1556 (2012).
87. Lu, X. & Kang, Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin. Cancer Res. 16, 5928-5935 (2010).
88. Tan, W. et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470, 548-553 (2011).
89. Rhim, A.D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349-361 (2012).
90. Branco-Price, C. et al. Endothelial cell HIF-1a and HIF-2a differentially regulate metastatic success. Cancer Cell 21, 52-65 (2012).
91. Calon, A. et al. Dependency of colorectal cancer on a TGF-b-driven program in stromal cells for metastasis initiation. Cancer Cell 22, 571-584 (2012).
92. Markowitz, S.D. & Bertagnolli, M.M. Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med. 361, 2449-2460 (2009).
93. Peinado, H. et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883-891 (2012).
94. Grange, C. et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 71, 5346-5356 (2011).
95. Kaplan, R.N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820-827 (2005).
96. Hiratsuka, S., Watanabe, A., Aburatani, H. & Maru, Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 8, 1369-1375 (2006).
97. Hiratsuka, S. et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol. 10, 1349-1355 (2008).
98. Psaila, B. & Lyden, D. The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer 9, 285-293 (2009).
99. Catena, R. et al. Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov. 3, 578-589 (2013).
100. Wilson, A. & Trumpp, A. Bone-marrow haematopoietic-stem-cell niches. Nat. Rev. Immunol. 6, 93-106 (2006).
101. Ghajar, C.M. et al. The perivascular niche regulates breast tumour dormancy. Nat. Cell Biol. 15, 807-817 (2013).
102. Kienast, Y. et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. 16, 116-122 (2010).
103. Gao, D. et al. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319, 195-198 (2008).
104. Lyden, D. et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7, 1194-1201 (2001).
105. Lyden, D. et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 401, 670-677 (1999).
106. Butler, J.M., Kobayashi, H. & Rafii, S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat. Rev. Cancer 10, 138-146 (2010).
107. Cao, P.D., Cheung, W.K. & Nguyen, D.X. Cell lineage specification in tumor progression and metastasis. Discov. Med. 12, 329-340 (2011).
108. Winslow, M.M. et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473, 101-104 (2011).
109. Snyder, E.L. et al. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol. Cell 50, 185-199 (2013).
110. Cheung, W.K. et al. Control of alveolar differentiation by the lineage transcription factors GATA6 and HOPX inhibits lung adenocarcinoma metastasis. Cancer Cell 23, 725-738 (2013).
111. Kouros-Mehr, H. et al. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13, 141-152 (2008).
112. Chou, J. et al. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat. Cell Biol. 15, 201-213 (2013).
113. Chakrabarti, R. et al. Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat. Cell Biol. 14, 1212-1222 (2012).
114. Guo, W. et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148, 1015-1028 (2012).
115. Nguyen, D.X. et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138, 51-62 (2009).
116. Oskarsson, T. et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat. Med. 17, 867-874 (2011).
117. Pratap, J. et al. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res. 68, 7795-7802 (2008).
118. Gupta, G.P. et al. ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc. Natl. Acad. Sci. USA 104, 19506-19511 (2007).
119. Swarbrick, A., Roy, E., Allen, T. & Bishop, J.M. Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response. Proc. Natl. Acad. Sci. USA 105, 5402-5407 (2008).
120. Malanchi, I. et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481, 85-89 (2012).
121. O'Connell, J.T. et al. VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc. Natl. Acad. Sci. USA 108, 16002-16007 (2011).
122. Kii, I. et al. Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. J. Biol. Chem. 285, 2028-2039 (2010).
123. Reticker-Flynn, N.E. et al. A combinatorial extracellular matrix platform identifies cell-extracellular matrix interactions that correlate with metastasis. Nat. Commun. 3, 1122 (2012).
124. Suvà, M.L., Riggi, N. & Bernstein, B.E. Epigenetic reprogramming in cancer. Science 339, 1567-1570 (2013).
125. Ryu, S. et al. Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration. Cancer Cell 23, 63-76 (2013).
126. Tiwari, N. et al. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell 23, 768-783 (2013).
127. Gupta, R.A. et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464, 1071-1076 (2010).
128. Celià-Terrassa, T. et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J. Clin. Invest. 122, 1849-1868 (2012).
129. Ocaña, O.H. et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 22, 709-724 (2012).
130. Tsai, J.H., Donaher, J.L., Murphy, D.A., Chau, S. & Yang, J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22, 725-736 (2012).
131. Tsuji, T. et al. Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res. 68, 10377-10386 (2008).
132. Korpal, M. et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat. Med. 17, 1101-1108 (2011).
133. Mejlvang, J. et al. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol. Biol. Cell 18, 4615-4624 (2007).
134. Joosse, S.A. et al. Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clin. Cancer Res. 18, 993-1003 (2012).
135. Zhang, L. et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci. Transl. Med. 5, 180ra148 (2013).
136. Zheng, H. & Kang, Y. Multilayer control of the EMT master regulators. Oncogene published online, doi:10.1038/onc.2013.128 (22 April 2013).
137. Chaffer, C.L. & Weinberg, R.A. A perspective on cancer cell metastasis. Science 331, 1559-1564 (2011).
138. Frisch, S.M. The epithelial cell default-phenotype hypothesis and its implications for cancer. Bioessays 19, 705-709 (1997).
139. Gao, D. et al. Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res. 72, 1384-1394 (2012).
140. Yates, C.C., Shepard, C.R., Stolz, D.B. & Wells, A. Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br. J. Cancer 96, 1246-1252 (2007).
141. Chao, Y.L., Shepard, C.R. & Wells, A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol. Cancer 9, 179 (2010).
142. Hüsemann, Y. et al. Systemic spread is an early step in breast cancer. Cancer Cell 13, 58-68 (2008).
143. Eyles, J. et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J. Clin. Invest. 120, 2030-2039 (2010).
144. Banys, M. et al. Hematogenous and lymphatic tumor cell dissemination may be detected in patients diagnosed with ductal carcinoma in situ of the breast. Breast Cancer Res. Treat. 131, 801-808 (2012).
145. Sanger, N. et al. Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int. J. Cancer 129, 2522-2526 (2011).
146. Stoecklein, N.H. & Klein, C.A. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int. J. Cancer 126, 589-598 (2010).
147. Makohon-Moore, A., Brosnan, J.A. & Iacobuzio-Donahue, C.A. Pancreatic cancer genomics: insights and opportunities for clinical translation. Genome Med. 5, 26 (2013).
148. Kim, M.Y. et al. Tumor self-seeding by circulating cancer cells. Cell 139, 1315-1326 (2009).
149. Norton, L. & Massague, J. Is cancer a disease of self-seeding? Nat. Med. 12, 875-878 (2006).
150. Braun, S. et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353, 793-802 (2005).
151. Bidard, F.C. et al. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin. Cancer Res. 14, 3306-3311 (2008).
152. Aft, R. et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 11, 421-428 (2010).
153. Gnant, M. et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679-691 (2009).
154. Comen, E., Norton, L. & Massague, J. Clinical implications of cancer self-seeding. Nat. Rev. Clin. Oncol. 8, 369-377 (2011).
155. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
156. Xu, X. et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 148, 886-895 (2012).
157. Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005 (2010).
158. Wu, X. et al. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 482, 529-533 (2012).
159. Liu, W. et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat. Med. 15, 559-565 (2009).
160. Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117 (2010).
161. Heitzer, E. et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 73, 2965-2975 (2013).
162. Campbell, P.J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113 (2010).
163. Shah, S.P. et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461, 809-813 (2009).
164. Vermaat, J.S. et al. Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin. Cancer Res. 18, 688-699 (2012).
165. Kuukasjärvi, T. et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 57, 1597-1604 (1997).
166. Zong, C., Lu, S., Chapman, A.R. & Xie, X.S. Genome-wide detection of single-nucleotide and copy-number variations of a single human cell. Science 338, 1622-1626 (2012).
167. Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90-94 (2011).
168. Gangnus, R., Langer, S., Breit, E., Pantel, K. & Speicher, M.R. Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin. Cancer Res. 10, 3457-3464 (2004).
169. Klein, C.A. et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360, 683-689 (2002).
170. Schmidt-Kittler, O. et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc. Natl. Acad. Sci. USA 100, 7737-7742 (2003).
171. Meng, S. et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 10, 8152-8162 (2004).
172. Steeg, P.S. Perspective: the right trials. Nature 485, S58-S59 (2012).
173. Coussens, L.M., Fingleton, B. & Matrisian, L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392 (2002).
174. Hu, G. et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 15, 9-20 (2009).
175. Acharyya, S. et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150, 165-178 (2012).
176. Gilbert, L.A. & Hemann, M.T. DNA damage-mediated induction of a chemoresistant niche. Cell 143, 355-366 (2010).
177. Carmeliet, P. & Jain, R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10, 417-427 (2011).
178. Braun, S. et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J. Clin. Oncol. 18, 80-86 (2000).
179. Townson, J.L. et al. Three-dimensional imaging and quantification of both solitary cells and metastases in whole mouse liver by magnetic resonance imaging. Cancer Res. 69, 8326-8331 (2009).
180. Naumov, G.N. et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res. Treat. 82, 199-206 (2003).
181. Jaini, R. et al. An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nat. Med. 16, 799-803 (2010).
182. Pantel, K., Brakenhoff, R.H. & Brandt, B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer 8, 329-340 (2008).
183. Goss, P.E. et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst. 97, 1262-1271 (2005).
184. Moy, B. & Goss, P.E. TEACH: Tykerb evaluation after chemotherapy. Clin. Breast Cancer 7, 489-492 (2007).
185. Sabnis, G., Goloubeva, O., Gilani, R., Macedo, L. & Brodie, A. Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment. Mol. Cancer Ther. 9, 46-56 (2010).
186. Goss, G.D. et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J. Clin. Oncol. 28, 49-55 (2010).
187. Alberts, S.R. et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. J. Am. Med. Assoc. 307, 1383-1393 (2012).
188. Loges, S., Mazzone, M., Hohensinner, P. & Carmeliet, P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15, 167-170 (2009).
189. Polzer, B. & Klein, C.A. Metastasis awakening: the challenges of targeting minimal residual cancer. Nat. Med. 19, 274-275 (2013).
190. Maheswaran, S. et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359, 366-377 (2008).
191. Hannemann, J. et al. Quantitative high-resolution genomic analysis of single cancer cells. PLoS ONE 6, e26362 (2011).
192. Zhang, X.H. et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16, 67-78 (2009).
193. Kobayashi, A. et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J. Exp. Med. 208, 2641-2655 (2011).
194. Marshall, J.C. et al. Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer. J. Natl. Cancer Inst. 104, 1306-1319 (2012).
195. Horak, C.E. et al. Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2. Cancer Res. 67, 11751-11759 (2007).
196. Horak, C.E., Lee, J.H., Marshall, J.C., Shreeve, S.M. & Steeg, P.S. The role of metastasis suppressor genes in metastatic dormancy. APMIS 116, 586-601 (2008).
197. Thiolloy, S. & Rinker-Schaeffer, C.W. Thinking outside the box: using metastasis suppressors as molecular tools. Semin. Cancer Biol. 21, 89-98 (2011).
198. Cook, L.M., Hurst, D.R. & Welch, D.R. Metastasis suppressors and the tumor microenvironment. Semin. Cancer Biol. 21, 113-122 (2011).
199. Gnant, M. Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. Curr. Cancer Drug Targets 9, 824-833 (2009).
200. Lipton, A. & Goessl, C. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone 48, 96-99 (2011).
201. Barton, M.K. Denosumab an option for patients with bone metastasis from breast cancer. CA Cancer J. Clin. 61, 135-136 (2011).
202. Buijs, J.T., Stayrook, K.R. & Guise, T.A. TGF-b in the bone microenvironment: role in breast cancer metastases. Cancer Microenviron. 4, 261-281 (2011).
203. Hensel, J.A., Flaig, T.W. & Theodorescu, D. Clinical opportunities and challenges in targeting tumour dormancy. Nat. Rev. Clin. Oncol. 10, 41-51 (2013).
204. Uhr, J.W. & Pantel, K. Controversies in clinical cancer dormancy. Proc. Natl. Acad. Sci. USA 108, 12396-12400 (2011).
205. Quesnel, B. Tumor dormancy and immunoescape. APMIS 116, 685-694 (2008).
206. Kantoff, P.W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
207. Hodi, F.S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
208. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
209. Weichselbaum, R.R. & Hellman, S. Oligometastases revisited. Nat. Rev. Clin. Oncol. 8, 378-382 (2011).
210. Pawlik, T.M. et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann. Surg. 241, 715-722, discussion 722-714 (2005).
211. Lussier, Y.A. et al. Oligo-and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS ONE 7, e50141 (2012); erratum 7, e50141 (2012). 212
212. Pantel K.,Diaz, L.A.Jr. & Polyak, K. Tracking tumor resistance using 'liquid biopsies'. Nat. Med. 19, 676-677 (2013).
213. Valastyan, S. et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137, 1032-1046 (2009).
214. Gatenby, R.A., Silva, A.S., Gillies, R.J. & Frieden, B.R. Adaptive therapy. Cancer Res. 69, 4894-4903 (2009).
215. Das Thakur, M. et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251-255 (2013).
216. Seruga, B. & Tannock, I.F. Intermittent androgen blockade should be
217. Klotz, L. Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer. Curr. Urol. Rep. 14, 159-167 (2013).
218. Pasquier, E., Kavallaris, M. & Andre, N. Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol. 7, 455-465 (2010).
219. Hanahan, D., Bergers, G. & Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105, 1045-1047 (2000).
220. Nguyen, D.X., Bos, P.D. & Massague, J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 9, 274-284 (2009).
221. van de Wouw, A.J., Janssen-Heijnen, M.L., Coebergh, J.W. & Hillen, H.F. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur. J. Cancer 38, 409-413 (2002).
222. Denève, E. et al. Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin. Chem. 59, 1384-1392 (2013).
223. Sugarbaker, P.H. Metastatic inefficiency: the scientific basis for resection of liver metastases from colorectal cancer. J. Surg. Oncol. Suppl. 3, 158-160 (1993).
224. Heiss, M.M. et al. Individual development and uPA-receptor expression of dissemi nated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat. Med. 1, 1035-1039 (1995).
225. Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112 (2013).
226. Dawson, S.J. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199-1209 (2013).
227. Parkinson, D.R. et al. Considerations in the development of circulating tumor cell technology for clinical use. J. Transl. Med. 10, 138 (2012).
228. Kamiya, N. et al. Clinical usefulness of bone markers in prostate cancer with bone metastasis. Int. J. Urol. 19, 968-979 (2012).
229. Ell, B. et al. Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell (in the press).
230. Kwong, G.A. et al. Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat. Biotechnol. 31, 63-70 (2013).
231. Erler, J.T. et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15, 35-44 (2009).
232. Kim, R.S. et al. Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer. PLoS ONE 7, e35569 (2012).
233. Kelloff, G.J. et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin. Cancer Res. 11, 2785-2808 (2005).
234. Walker-Samuel, S. et al. In vivo imaging of glucose uptake and metabolism in tumors. Nat. Med. 19, 1067-1072 (2013).
235. Padhani, A.R., Krohn, K.A., Lewis, J.S. & Alber, M. Imaging oxygenation of human tumours. Eur. Radiol. 17, 861-872 (2007).
236. Choe, Y.S. & Lee, K.H. Targeted in vivo imaging of angiogenesis: present status and perspectives. Curr. Pharm. Des. 13, 17-31 (2007).
237. Emblem, K.E. et al. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat. Med. 19, 1178-1183 (2013).
238. Benz, M.R. et al. 18F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J. Nucl. Med. 52, 1684-1689 (2011).
239. Hicke B.J.,et al.Tumor targeting by an aptamer. J. Nucl. Med. 47, 668-678 (2006).